Influence of İnterferon alpha-2a Treatment on Monocyte Subsets in Patients with Uveitis

Abstract

Introduction:Interferonais a type-I interferon molecule with antiviral and antineoplastic properties. Interferonatreatment is also used in the management of uveitis and believed to have immunomodulatory properties demonstrated by increased number of regulatory T cells. The aim of this study was to define the influence of interferona-2a treatment on monocyte subsets in patients with uveitis.Materials and Methods:Six patients with uveitis and 7 healthy control subjects were included in this study. Blood samples were obtained from the uveitis patients before treatment with interferona-2a and at the 1st month of treatment (or at clinical remission). Peripheral blood mononuclear cells were stained with anti-CD16, anti-CD14, anti-PD-1, anti-CTLA-4, anti-LAG-3, anti-TIM-3 and anti-TIGIT antibodies and analyzed with flow cytometry. Data were analyzed with FlowJo software and statistical analysis was performed with SPSS 21.0 software.Results:Six patients with uveitis (5 Behçet’s, 1 Eales disease, mean age: 29.0±3.8 years, 4 male, 2 female) and 7 healthy control subjects (mean age: 28.4±4.9 years, 3 male, 4 female) were included. The number of CD14+CD16-classical monocytes were increased and CD16+non-classical monocytes were decreased in patients with active uveitis compared to controls (p=0.037 and p=0.045) and this difference disappeared after treatment with interferona-2a. There was no difference in immune checkpoint receptor expressions between groups at baseline. PD-1 expression increased significantly after interferona-2a treatment (p=0.01).Conclusion:Interferona-2a treatment increases the ratio of non-classical monocytes and their expression of PD-1. These changes may be associated with the previously demonstrated immunomodulatory effects of interferona-2a in patients with uveitis.